Меплазумаб (Meplazumab)
Международное непатентованное наименование
Меплазумаб (Meplazumab)
Торговое наименование
Ketantin
Производитель, страна
Jiangsu Pacific Meinuoke Bio Pharmaceutical Co Ltd, China
Механизм действия
Meplazumab (Ketantin®) is a lyophilized powder for injection of small volume. The main active ingredient of the product, meplazumab, is a humanized immunoglobulin (Ig) G2 monoclonal antibody, consisting of the complementary-determining regions of anti CD147 murine antibody and the human framework region. It acts as an erythrocytic stage-macromolecular antibody drug that has the potential to mediate both treatment and prophylaxis of falciparum malaria.
Публикации COVID-19
, , et al. Meplazumab treats COVID-19 pneumonia: an open-labelled, concurrent controlled add-on clinical trial. DOI: 10.1101/2020.03.21.20040691.
Клинические исследования
1.
Название протокола
Single Center, Single Arm, Open Clinical Study to Access Safety and Initial Efficacy of Anti-CD147 Humanized Meplazumab for Injection to Treat With 2019-nCoV Pneumonia
Дата начала и окончания КИ
February 3, 2020 - December 31, 2020
Название организации, проводящей КИ
Tang-Du Hospital
Страны
China
Фаза
I-II
Кол-во пациентов
20